



## **BIO CEO and Investor Conference to Webcast Alkermes' Corporate Presentation**

February 8, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2006--Alkermes, Inc. (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live by The Biotechnology Industry Organization (BIO) on Tuesday, February 14, 2006 at 11:00 a.m. EST. The presentation will be webcast from The Waldorf Astoria Hotel in New York and may be accessed under the investor relation's tab at [www.alkermes.com](http://www.alkermes.com). The presentation will be archived for 14 days.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, RISPEDAL(R) CONSTA(R) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson. The Company's lead proprietary product candidate, VIVITROL(TM) (naltrexone for extended-release injectable suspension), is being developed as a once-monthly injection for the treatment of alcohol dependence. The Company has a pipeline of extended-release injectable products and pulmonary drug products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Debra Koufos  
Associate, Corporate Communications  
Alkermes, Inc.  
(617) 583-6220

SOURCE: Alkermes, Inc.